Literature DB >> 26929980

Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach.

Zheng Zhao1, Li Xie2, Lei Xie3,4, Philip E Bourne5.   

Abstract

Targeted polypharmacology of kinases has emerged as a promising strategy to design efficient and safe therapeutics. Here, we perform a systematic study of kinase-ligand binding modes for the human structural kinome at scale (208 kinases, 1777 unique ligands, and their complexes) by integrating chemical genomics and structural genomics data and by introducing a functional site interaction fingerprint (Fs-IFP) method. New insights into kinase-ligand binding modes were obtained. We establish relationships between the features of binding modes, the ligands, and the binding pockets, respectively. We also drive the intrinsic binding specificity and which correlation with amino acid conservation. Third, we explore the landscape of the binding modes and highlight the regions of "selectivity pocket" and "selectivity entrance". Finally, we demonstrate that Fs-IFP similarity is directly correlated to the experimentally determined profile. These improve our understanding of kinase-ligand interactions and contribute to the design of novel polypharmacological therapies targeting kinases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26929980      PMCID: PMC4865454          DOI: 10.1021/acs.jmedchem.5b02041

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  95 in total

1.  The ins and outs of selective kinase inhibitor development.

Authors:  Susanne Müller; Apirat Chaikuad; Nathanael S Gray; Stefan Knapp
Journal:  Nat Chem Biol       Date:  2015-11       Impact factor: 15.040

2.  Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.

Authors:  Julian Engel; André Richters; Matthäus Getlik; Stefano Tomassi; Marina Keul; Martin Termathe; Jonas Lategahn; Christian Becker; Svenja Mayer-Wrangowski; Christian Grütter; Niklas Uhlenbrock; Jasmin Krüll; Niklas Schaumann; Simone Eppmann; Patrick Kibies; Franziska Hoffgaard; Jochen Heil; Sascha Menninger; Sandra Ortiz-Cuaran; Johannes M Heuckmann; Verena Tinnefeld; René P Zahedi; Martin L Sos; Carsten Schultz-Fademrecht; Roman K Thomas; Stefan M Kast; Daniel Rauh
Journal:  J Med Chem       Date:  2015-08-31       Impact factor: 7.446

Review 3.  FDA-approved small-molecule kinase inhibitors.

Authors:  Peng Wu; Thomas E Nielsen; Mads H Clausen
Journal:  Trends Pharmacol Sci       Date:  2015-05-12       Impact factor: 14.819

4.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Authors:  Annette O Walter; Robert Tjin Tham Sjin; Henry J Haringsma; Kadoaki Ohashi; Jing Sun; Kwangho Lee; Aleksandr Dubrovskiy; Matthew Labenski; Zhendong Zhu; Zhigang Wang; Michael Sheets; Thia St Martin; Russell Karp; Dan van Kalken; Prasoon Chaturvedi; Deqiang Niu; Mariana Nacht; Russell C Petter; William Westlin; Kevin Lin; Sarah Jaw-Tsai; Mitch Raponi; Terry Van Dyke; Jeff Etter; Zoe Weaver; William Pao; Juswinder Singh; Andrew D Simmons; Thomas C Harding; Andrew Allen
Journal:  Cancer Discov       Date:  2013-09-24       Impact factor: 39.397

5.  Multiple and single binding modes of fragment-like kinase inhibitors revealed by molecular modeling, residue type-selective protonation, and nuclear overhauser effects.

Authors:  Keith L Constantine; Luciano Mueller; William J Metzler; Patricia A McDonnell; Gordon Todderud; Valentina Goldfarb; Yi Fan; John A Newitt; Susan E Kiefer; Mian Gao; David Tortolani; Wayne Vaccaro; John Tokarski
Journal:  J Med Chem       Date:  2008-09-05       Impact factor: 7.446

6.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

7.  Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.

Authors:  Li Xie; Thomas Evangelidis; Lei Xie; Philip E Bourne
Journal:  PLoS Comput Biol       Date:  2011-04-28       Impact factor: 4.475

8.  The Pfam protein families database.

Authors:  Marco Punta; Penny C Coggill; Ruth Y Eberhardt; Jaina Mistry; John Tate; Chris Boursnell; Ningze Pang; Kristoffer Forslund; Goran Ceric; Jody Clements; Andreas Heger; Liisa Holm; Erik L L Sonnhammer; Sean R Eddy; Alex Bateman; Robert D Finn
Journal:  Nucleic Acids Res       Date:  2011-11-29       Impact factor: 16.971

9.  A multidimensional strategy to detect polypharmacological targets in the absence of structural and sequence homology.

Authors:  Jacob D Durrant; Rommie E Amaro; Lei Xie; Michael D Urbaniak; Michael A J Ferguson; Antti Haapalainen; Zhijun Chen; Anne Marie Di Guilmi; Frank Wunder; Philip E Bourne; J Andrew McCammon
Journal:  PLoS Comput Biol       Date:  2010-01-22       Impact factor: 4.475

10.  Historeceptomic Fingerprints for Drug-Like Compounds.

Authors:  Evgeny Shmelkov; Arsen Grigoryan; James Swetnam; Junyang Xin; Doreen Tivon; Sergey V Shmelkov; Timothy Cardozo
Journal:  Front Physiol       Date:  2015-12-18       Impact factor: 4.566

View more
  11 in total

1.  A benchmark driven guide to binding site comparison: An exhaustive evaluation using tailor-made data sets (ProSPECCTs).

Authors:  Christiane Ehrt; Tobias Brinkjost; Oliver Koch
Journal:  PLoS Comput Biol       Date:  2018-11-08       Impact factor: 4.475

2.  Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.

Authors:  Zheng Zhao; Qingsong Liu; Spencer Bliven; Lei Xie; Philip E Bourne
Journal:  J Med Chem       Date:  2017-04-04       Impact factor: 7.446

3.  On the importance of composite protein multiple ligand interactions in protein pockets.

Authors:  Sam Tonddast-Navaei; Bharath Srinivasan; Jeffrey Skolnick
Journal:  J Comput Chem       Date:  2016-11-16       Impact factor: 3.376

4.  VariFunNet, an integrated multiscale modeling framework to study the effects of rare non-coding variants in Genome-Wide Association Studies: applied to Alzheimer's Disease.

Authors:  Qiao Liu; Chen Chen; Annie Gao; Hang Hang Tong; Lei Xie
Journal:  Proceedings (IEEE Int Conf Bioinformatics Biomed)       Date:  2017-12-18

5.  Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants.

Authors:  Zheng Zhao; Lei Xie; Philip E Bourne
Journal:  J Chem Inf Model       Date:  2019-01-11       Impact factor: 4.956

6.  Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome.

Authors:  Zheng Zhao; Lei Xie; Philip E Bourne
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

7.  Chemistry-based molecular signature underlying the atypia of clozapine.

Authors:  T Cardozo; E Shmelkov; K Felsovalyi; J Swetnam; T Butler; D Malaspina; S V Shmelkov
Journal:  Transl Psychiatry       Date:  2017-02-21       Impact factor: 6.222

8.  Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery.

Authors:  Zheng Zhao; Philip E Bourne
Journal:  J Proteome Res       Date:  2020-09-29       Impact factor: 4.466

9.  Recon3D enables a three-dimensional view of gene variation in human metabolism.

Authors:  Elizabeth Brunk; Swagatika Sahoo; Daniel C Zielinski; Ali Altunkaya; Andreas Dräger; Nathan Mih; Francesco Gatto; Avlant Nilsson; German Andres Preciat Gonzalez; Maike Kathrin Aurich; Andreas Prlić; Anand Sastry; Anna D Danielsdottir; Almut Heinken; Alberto Noronha; Peter W Rose; Stephen K Burley; Ronan M T Fleming; Jens Nielsen; Ines Thiele; Bernhard O Palsson
Journal:  Nat Biotechnol       Date:  2018-02-19       Impact factor: 54.908

10.  Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization.

Authors:  Obdulia Rabal; Andrea Castellar; Julen Oyarzabal
Journal:  J Cheminform       Date:  2018-07-21       Impact factor: 5.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.